CONGENITAL ADRENAL HYPERPLASIA
Clinical trials for CONGENITAL ADRENAL HYPERPLASIA explained in plain language.
Never miss a new study
Get alerted when new CONGENITAL ADRENAL HYPERPLASIA trials appear
Sign up with your email to follow new studies for CONGENITAL ADRENAL HYPERPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to cut risky steroid use for rare hormone disorder
Disease control TerminatedThis study tested whether a drug called Tildacerfont could help adults with classic congenital adrenal hyperplasia (CAH) safely reduce their high daily steroid doses. One hundred participants were randomly assigned to receive either Tildacerfont or a placebo for 24 weeks, followe…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Trial tests new drug to help kids with rare hormone disorder
Disease control TerminatedThis study tested a drug called tildacerfont in children aged 2 to 17 with congenital adrenal hyperplasia (CAH), a rare genetic hormone disorder. The main goal was to see if the drug was safe and if it could help control the disease, potentially allowing for a reduction in the st…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Early halted trial explores new way to treat rare childhood hormone disorder
Disease control TerminatedThis early-stage study tested whether adding a medication called abiraterone acetate to standard treatment could help young children with a rare inherited hormone disorder (congenital adrenal hyperplasia) safely reduce their daily steroid dose. The goal was to find the lowest eff…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC